化疗
医学
内科学
耐受性
危险系数
肿瘤科
胃肠病学
阶段(地层学)
不利影响
外科
置信区间
生物
古生物学
作者
Jiaying Lu,Zhaohui Qin,Ji Ma,Nan Yao,Wanxi Qu,Li Cui,Shiwang Yuan,Yuanhu Yao
标识
DOI:10.1080/1120009x.2023.2247206
摘要
AbstractTo evaluate the anti-tumor efficacy and tolerability of programmed cell death protein 1 (PD-1) inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for unresectable esophageal squamous cell carcinoma (ESCC) patients at stage IV in a real-world cohort. All unresectable ESCC patients at stage IV who initiated first-line therapy with PD-1 inhibitors plus chemotherapy between August 2018 and March 2021 in a general hospital in China were retrospectively analyzed in this study. Propensity score matching (1:1) with control patients receiving chemotherapy alone was performed. Overall survival (OS) and progression-free survival (PFS) were assessed by the Kaplan–Meier method. In this study, fifty patients (n = 25 each group) were included, all of whom could be evaluated for efficacy. PD-1 inhibitors plus chemotherapy exhibited better OS than chemotherapy alone (median 15.8 vs 12.4 months, hazard ratio [HR] 0.46 [95% CI 0.23–0.95]; P = 0.036). The median PFS for the PD-1 inhibitors plus chemotherapy group was 8.7 months compared with 6.1 months for the chemotherapy group (HR 0.48 [95% CI 0.26–0.90]; P = 0.014). Adverse events (AEs) of grade 3 or above related to treatment were found in 24.0% and 32.0% of the PD-1 inhibitors plus chemotherapy and chemotherapy alone groups, respectively. PD-1 inhibitors plus chemotherapy exhibited durable anti-tumor activity and relatively controllable safety as first-line therapy for unresectable ESCC patients at stage IV, but these results need to be confirmed by further research.Keywords: Esophageal squamous cell carcinomaprogrammed cell death protein 1chemotherapyimmunotherapystage IVoverall survival Disclosure statementThe authors declare that they have no potential conflict of interest relevant to this article.
科研通智能强力驱动
Strongly Powered by AbleSci AI